KPV in experimental colitis
PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation
Dalmasso G et al. · Gastroenterology
Study record
- Population
- Formulation
- Route
- Dose & frequency
- Study design
- Duration
- Reported findings
- Adverse events
What it supports
Mechanistic and preclinical evidence about KPV.
What it does not establish
Not a human clinical trial. Does not establish efficacy, dosing, or safety of KLOW.
Funding
Not extracted in this pilot
Checked 2026-09-08 · Abstract-level extraction · Clinical/editorial review pending
Open original publication